Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

efficacy of CLS001 in up to 240 subjects with papulopustular rosacea. The primary efficacy endpoint is the mean percent reduction in the number of inflammatory lesions. This study is expected to be completed by the end of 2007.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): Good Laboratory Practices ("GLP") non-clinical studies were initiated in April 2007. Timing for completion of the GLP studies is dependent upon (1) additional manufacturing process development work; (2) initiation of the remaining required GLP studies; and (3) financial resources. Prior to initiating clinical trials in humans with MX-2401 the Company will need to complete the GLP studies, manufacture clinical trial GMP quality MX-2401, submit and obtain regulatory approval for initiating clinical studies, and various other activities. A $9.3 million investment commitment from Technology Partnerships Canada is associated with this program.

MX-4565 (small molecule; treatment of neurodegenerative diseases): In June 2007 we were awarded a grant from the Michael J. Fox Foundation to fund research in our MX-4565 program. The grant award agreement provides Elan Pharmaceuticals with a limited right to license the technology arising from the project for certain uses in the field of human disease.

Annual General Meeting: The Company hosted its 2007 Annual General Meeting yesterday. Re-elected to the board of directors were: David Scott (Chairman), Michael Abrams, Jim DeMesa, Richard DeVries, Alistair Duncan, Steve Gillis, Colin Mallet, Walter Moos, and Keith Schilit.

Other Matters: Further to the notice of early termination of our Vancouver facility lease due to a redevelopment of the site the Company has entered into an offer to lease approximately 5,000 square feet of space (currently office space, no labs) in close proximity to the existing facility and has made an offer to lease approximately 6,000 to 9,000 square feet of lab space in the Vancouver a
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
(Date:8/3/2015)... WA (PRWEB) , ... August 03, 2015 , ... ... and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory equipment. ... steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution for ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... TX, USA (PRWEB) , ... July 30, 2015 ... ... and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , ... positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... Company posts record quarterly revenues of $27.2 million, ... CRY ),a biomaterials, medical device and tissue ... quarter of 2008 increased 18 percent to,$27.2 million ... of 2007.,Excluding orthopaedic tissue processing revenues of $297,000 ...
... 31 Alsius Corporation,(Nasdaq: ALUS ), the ... critically ill patients, today,announced that it will hold ... results and provide a corporate update. Bill Worthen,president ... 1:30 p.m. Pacific Time,(4:30 p.m. Eastern Time) on ...
... Including Industrial ... ... Bioscience (Nasdaq:,PURE) today announced an agreement with DuraBan International ... DuraBan,s DuraClean(TM) brand., (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ), ...
Cached Biology Technology:CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 2CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 3CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 4CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 5CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 6CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 7CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 8CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 9CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 10CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 11Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 3PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 4
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... Washington, D.C. -- Plant science is key to addressing the ... Carnegie,s David Ehrhardt and Wolf Frommer. In a Perspective published ... that the development of new technology is key to transforming ... Plants serve as the conduit of energy into the biosphere, ...
... Freshwater ecosystems in northern regions are home to significantly ... to evidence that regions with vanishing waters contain unique ... -- which are actually tiny crustaceans -- comes from ... in the journal Zootaxa . The researchers ...
... WASHINGTON -- The exhaust fumes from gasoline vehicles contribute ... air pollution-secondary organic aerosols (SOA)-than those from diesel ,vehicles, ... Cooperative Institute for Research in ,Environmental Sciences (CIRES), NOAA,s ... "The surprising result we found was that it wasn,t ...
Cached Biology News:The future of plant science - a technology perspective 2Unexpected crustacean diversity discovered in northern freshwater ecosystems 2AGU: Gasoline worse than diesel when it comes to some types of air pollution 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... its SpliceArray service, ExonHit can design custom ... with your gene list. Proprietary algorithms ... design microarray probes from high quality, spliced ... splice event contained in a custom SpliceArray ...
... DX's sensitivity of DNA detection has been improved. ... an agarose gel can be detected > 20 ... be purified by organic solvent extraction or with ... worked well.) DNA excised from agarose gel ...
... The RapidTrace SPE Workstation is a modular, ... extraction platform. Utilizing 1ml or 3ml industry ... up to 100 samples in less than ... loaded with 10 cartridges, and up to ...
Biology Products: